FY2029 Earnings Forecast for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA) – Stock analysts at HC Wainwright lowered their FY2029 EPS estimates for shares of Savara in a report issued on Wednesday, August 12th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $0.09 for the year, down from their prior estimate of $0.11. The consensus estimate for Savara’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Savara’s FY2030 earnings at $0.37 EPS.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02).

Other equities research analysts have also recently issued research reports about the company. Oppenheimer assumed coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Stock Up 2.3%

Savara stock opened at $5.70 on Thursday. The company’s 50-day moving average price is $5.65 and its two-hundred day moving average price is $5.49. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.17 billion, a P/E ratio of -9.83 and a beta of 0.29. Savara has a twelve month low of $2.43 and a twelve month high of $7.01.

Institutional Trading of Savara

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Savara during the second quarter worth approximately $76,966,000. Polar Capital Holdings Plc bought a new stake in shares of Savara in the fourth quarter valued at approximately $50,086,000. RTW Investments LP bought a new stake in shares of Savara in the fourth quarter valued at approximately $35,893,000. VR Adviser LLC grew its position in Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after buying an additional 5,626,624 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Savara during the 4th quarter worth $27,496,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.